" class="no-js "lang="en-US"> Clyde Biosciences - Medtech Alert
Thursday, March 28, 2024
Clyde Biosciences | Pharmtech Focus

Clyde Biosciences

About Clyde Biosciences

Clyde Biosciences

Clyde Biosciences is the leading cardiac cell analysis solution provider, used by the biopharma industry to help bring better, safer drugs to market. Our services are conducted on the CellOPTIQ® platform, a unique technology designed to eliminate the risk of false positive or false negative results. CellOPTIQ® provides clients with unparalleled data at a time when the industry needs it most, offering greater data resolution than any other assay, doing so in one experiment. With over 100 years of combined electrophysiology and computational experience Clyde Biosciences’ scientists work with pharmaceutical companies to design testing, data interpretation, and reporting packages that suit the efficacy and safety assessment objectives.

Related Story

Axol Bioscience Introduces CiPA-validated Human Stem Cell-derived Ventricular Cardiomyocytes to Help Improve Drug Discovery

June 8 2022

Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science […]